期刊
GENE THERAPY
卷 17, 期 2, 页码 272-280出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2009.134
关键词
SIN vector production; stable packaging lines; gamma-retroviral vectors
类别
资金
- German Ministry for Research and Education
- Deutsche Forschungsgemeinschaft [SPP1230]
- CGD Research Trust [J4G/04B/GT]
- European Union [LSHB-CT-2004-005242, LSHB-CT-2006-018933]
- Else-Krorner-Fresenius-Stiftung
- MRC [G0501969] Funding Source: UKRI
- Medical Research Council [G0501969] Funding Source: researchfish
The clinical application of self-inactivating (SIN) retroviral vectors has been hampered by the lack of reliable and efficient vector production technologies. To enable production of SIN gamma-retroviral vectors from stable producer clones, a new PG13-based packaging cell, known as PG368, was developed. Viral vector expression constructs can be reliably inserted at a predefined genomic locus of PG368 packaging cells by an Flp-recombinase-mediated targeted cassette exchange (RMCE) reaction. A new, carefully designed vector-targeting construct, pEMTAR-1, eliminated the co-packaging of the selectable marker gene used for the identification of successful recombination at the predefined genomic locus and thus, improved the safety of the production system. Selected clones produced vector supernatants at consistent titers. The targeted insertion of therapeutically relevant SIN vectors for chronic granulomatous disease and X-linked severe combined immunodeficiency into PG368 cells results in stable titers within the range necessary for clinical application. The production of retroviral SIN vectors from stable clinical-grade producer cells is feasible and will contribute to the safe production and application of SIN gamma-retroviral vectors for clinical trials. Gene Therapy (2010) 17, 272-280; doi: 10.1038/gt.2009.134; published online 29 October 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据